fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

Posted on 2/2/14

In Other News...

Campbellsville University Honors 177 Teachers for Excellence in Teaching

CAMPBELLSVILLE, Ky. (7/27/15) — Campbellsville University honored 177 teachers from 66 school districts throughout… Read More

OPS, Kentucky Wesleyan College to Build State-of-the- Art Track, Field Facility

OWENSBORO, Ky. (7/28/15) — Owensboro Public Schools will work collaboratively with Kentucky Wesleyan College to build a… Read More

Most Read This Week

July 23, 2015 14522

UPDATE: Family Confirms Body of Missing Teen…

by Shawn Freels, SurfKY News
July 27, 2015 4896

Death of Central City Man in Dawson Springs Under…

by SurfKY News
July 23, 2015 4342

Woman Accused of Striking Juvenile with Metal Belt

by SurfKY News
July 22, 2015 4285

No. 9 Steakhouse Suffers Fire; Owners Vow to…

by Doreen Dennis, SurfKY News
July 22, 2015 3953

UPDATE - GPD Recovers Stolen Vehicle, Arrest Made

by SurfKY News

Most Read This Month

July 02, 2015 19398

Emergency Response Team on Scene of Standoff on…

by Doreen Dennis, SurfKY News
July 17, 2015 15451

Muhlenberg Most Wanted - Top 10

by SurfKY News

Stories Trending Now

July 27, 2015 4896

Death of Central City Man in Dawson Springs Under…

by SurfKY News
July 27, 2015 3565

School System Announces Free Lunch/Breakfast at…

by SurfKY News
July 27, 2015 1731

Family Needs Help in Paying 18-Year-Old's Funeral…

by SurfKY News
July 28, 2015 1426

Hanson Youth Wins Soap Box Derby World…

by Tammy Holloway, SurfKY News
July 27, 2015 1294

Baptist Health Names Regional Marketing, Public…

by SurfKY News
July 27, 2015 1224

Madisonville Police Arrest Reports Released –…

by SurfKY News
July 27, 2015 1177

New Madisonville Public Parking Area Announcement

by SurfKY News
July 28, 2015 1053

Heavy Rains, Two Wrecks Impeded WKP Travel

by Doreen Dennis, SurfKY News
July 28, 2015 977

Hopkins County Grand Jury Indictments

by SurfKY News
July 27, 2015 910

Dawson Springs Police Reports Released

by SurfKY News